<img src="https://ml.globenewswire.com/Resource/Download/4d3d3283-c57d-401e-9e1b-53f17e22d76b?size=2" nborder="0" align="left" hspace="5" vspace="5" title="Kymera-Logo-RGB-Denim+Marigold - High Res.png" alt="Kymera Therapeutics, Inc."/>WATERTOWN, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=6QjfIiC_WL-j6qCrCelqfk_ZqR677X8eol-dUCxXkJKSSvvv_DWbwSbA5AZumfappBftdvDrXX3KIa6E3X8WfWy69yYUTIHdgqOJz5jQ5_Q=" rel="nofollow" target="_blank" title="Kymera Therapeutics, Inc.">Kymera Therapeutics, Inc.</a> (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report second quarter 2026 financial results on August 5, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via <a href="https://www.globenewswire.com/Tracker?data=Rfya-el3IF42QAew4dtqwhasGG3jfGNs7A_3lrynZ6xL4XEadJMIqd3hUODXEmksbyX5LE2lEr508FRsQxmFG1dQc-EzbI5zF5E-geSWOObACoOsLTzf8Mk0V4_g9T0lvRdsr4QQYzNlVQ56WNAmlg==" rel="nofollow" target="_blank" title="">this link</a>, or visit “<a href="https://www.globenewswire.com/Tracker?data=m-IgM7r6_5TH05iVvWtNQ8MfnW2A9VcP8SWr9pX0aafVd--TItduKCeKCpFX7WvyHh0x-xHN1Sx899oB1VjWDyJprK1BVQnPZDlqI7LJNoUia4agS2N6cBjZCinohIvl" rel="nofollow" target="_blank" title="News and Events">News and Events</a>” in the Investors section of the Company’s website at <a href="https://www.globenewswire.com/Tracker?data=ZsmYvR3ggRfmsec10fTaVbG3Yz4p-Y5dAy4_mxrPemi42UrOPzN4e1qRMlq0BQmsQqPmWpBLmryqPoE7woTA7Ekun48ZzMzBmUwNe-HLfB0=" rel="nofollow" target="_blank" title="www.kymeratx.com">www.kymeratx.com</a>. A replay of the webcast will be archived and available following the event. About Kymera Therapeutics  Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit <a href="https://www.globenewswire.com/Tracker?data=ZsmYvR3ggRfmsec10fTaVbxKPu0Q2mNfcWoJSIAiBraMfYKBJFWvafjFuGLlF8WMdAaNdBI7Kwfc60bYkKFeGiqXc9vePKsl6upcl9QPTSA=" rel="nofollow" target="_blank" title="www.kymeratx.com">www.kymeratx.com</a> or follow us on <a href="https://www.globenewswire.com/Tracker?data=jlUO0htdtR4b5WyTNytfczwH5B4C_uIQ6l3hXTvIKargMRgfRhknxh3U7-HeBuG28ee_GdOdgLG4MZ3yOlG4XA==" rel="nofollow" target="_blank" title="X">X</a> or <a href="https://www.globenewswire.com/Tracker?data=IHGN01I4I-hMHtyVdVi4WLVVmckTHirHH_Yyx3uJ4kB3_tBn4-s3UP-vsXfLvE4N0-44qr0k5t78O2MHZ0R0MJTl0Boteu3MwusdjPJTrLjpoM2-foH3WjNCDYontDas" rel="nofollow" target="_blank" title="LinkedIn">LinkedIn</a>. Investor Contact:  Justine Koenigsberg <a href="https://www.globenewswire.com/Tracker?data=x3qq1rXz_6BLpAfwnWMZO5G-rMM_XsoBk-raTFKMsl772ZaJ2WfzG0bjZ_jtYT1YdZNDCYn2WEBEV-lcMUqXkLu2h6PA5fIqo4rN9qd6aNI=" rel="nofollow" target="_blank" title="investors@kymeratx.com">investors@kymeratx.com</a> 857-285-5300  Media Contact: Matthew Henson <a href="https://www.globenewswire.com/Tracker?data=PylyDguO0HN8P1t2el5wkv93Td6XWu0uY5xMbyhLQSm7KyA0n0qyF7AHHIUhODcUBtu4tzwvO1JQiPy2aIg8t-FMmpdphROJiuCs13AzuMk=" rel="nofollow" target="_blank" title="media@kymeratx.com">media@kymeratx.com</a> 857-285-5300 <img alt="" src='https://ml.globenewswire.com/media/NDdlNDJhNDgtZWI3NS00YzI5LWJkZTItZTExNTVlZTI4MGUzLTEyMTIzODUtMjAyNi0wNy0yOC1lbg==/tiny/Kymera-Therapeutics-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn